The overall goal of the Quantitative Imaging Core Shared Resource is to enhance the scientific quality of clinical studies, by offering a single point of entry for Moffitt Cancer Center (MCC) members to access traditional and advanced quantitative image analysis services.
Efforts are organized around three Specific Aims, which are to:
Aim 1: maintain and improve the high reliability and fast turnaround times for RECIST (Response Evaluation Criteria in Solid Tumors)and other standard tumor assessment metrics;
Aim 2: improve therapeutic trials at MCC by translating research advances in radiomics and multi-parameter MRI (mpMRI) analyses into turnkey imaging biomarker services; and
Aim 3: provide members with access to non-traditional imaging endpoints for therapeutic trials.
The Quantitative Imaging Core provides quantitative image-based tumor metrics to support investigator-initiated, cooperative group, and industry-sponsored clinical trials at MCC. The core provides the support and services necessary to integrate both traditional and innovative imaging endpoints into clinical trials and provides quality assurance and control throughout the process to yield scientifically valid results. With rapid advances in treatment paradigms such as immunotherapies, the Quantitative Imaging Core provides improved imaging endpoints to meet the needs of these cutting-edge studies of MCC members.
Natarajan Raghunand, PhD
Donald Klippenstein, MD - (813) 745-2058
Core Facility Manager:
Olya Stringfield, PhD
This work has been supported in part by the Image Response Assessment Team Core at the H. Lee Moffitt Cancer Center & Research Institute, a comprehensive cancer center designated by the National Cancer Institute and funded in part by Moffitt’s Cancer Center Support Grant (P30-CA076292)